P

Inventor

TEPLYAKOV ALEXEY

US30 patents
⚠️ This page may combine multiple inventors who share the name “TEPLYAKOV ALEXEY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

JANSSEN BIOTECH INC

20 patents
US9102737B2Aug 11, 2015

Human anti-CD27 antibodies, methods and uses

JANSSEN BIOTECH INC36 citations96
US9522957B2Dec 20, 2016

Method of treating an inflammatory condition by administering toll-like 3 receptor antagonists

JANSSEN BIOTECH INC10 citations92
US9683046B2Jun 20, 2017

Nucleic acid molecules encoding anti-CD27 antibodies

JANSSEN BIOTECH INC7 citations83
US9481731B2Nov 1, 2016

Toll-like receptor 3 antagonists

JANSSEN BIOTECH INC9 citations83
US8999333B2Apr 7, 2015

Human tissue factor antibody and uses thereof

JANSSEN BIOTECH INC9 citations83
US8951525B2Feb 10, 2015

Human tissue factor antibody and uses thereof

JANSSEN BIOTECH INC11 citations83
US10301392B2May 28, 2019

Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies

JANSSEN BIOTECH INC3 citations72
US10669343B2Jun 2, 2020

Anti-CD154 antibodies and methods of using them

JANSSEN BIOTECH INC3 citations71
US11884722B2Jan 30, 2024

Anti-GPRC5D antibodies, bispecific antigen binding molecules that bind GPRC5D and CD3, and uses thereof

JANSSEN BIOTECH INC1 citations69
US11414484B2Aug 16, 2022

Anti-CCL17 antibodies

JANSSEN BIOTECH INC1 citations68
US10844122B2Nov 24, 2020

Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof

JANSSEN BIOTECH INC4 citations68
US10562948B2Feb 18, 2020

GM-CSF variants and methods of use

JANSSEN BIOTECH INC1 citations66
US9932404B2Apr 3, 2018

Methods of reducing clinical symptoms of viral infection by administering a toll-like receptor 3 antagonist

JANSSEN BIOTECH INC1 citations62
US11732050B2Aug 22, 2023

Neutralizing human anti-CD27 antibodies

JANSSEN BIOTECH INC0 citations61
US11421037B2Aug 23, 2022

Nucleic acids encoding anti-CD154 antibodies

JANSSEN BIOTECH INC0 citations61
US10544229B2Jan 28, 2020

Agonistic antibodies specifically binding CD40 and methods of use

JANSSEN BIOTECH INC1 citations60
US9944697B2Apr 17, 2018

Anti-CCL17 antibodies

JANSSEN BIOTECH INC1 citations58
US11208450B2Dec 28, 2021

GM-CSF variants and methods of use

JANSSEN BIOTECH INC0 citations56
US11787875B2Oct 17, 2023

Materials and methods for improved single chain variable fragments

JANSSEN BIOTECH INC1 citations54
US10689453B2Jun 23, 2020

Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies

JANSSEN BIOTECH INC0 citations51

CUNNINGHAM MARK

5 patents

JANSSEN PHARMACEUTICA NV

3 patents

ALMAGRO JUAN CARLOS

1 patent

JANNSEN BIOTECH INC

1 patent